On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer
dc.contributor.author | McGinn, Cornelius J. | en_US |
dc.contributor.author | Lawrence, Theodore S. | en_US |
dc.contributor.author | Zalupski, Mark M. | en_US |
dc.date.accessioned | 2006-04-19T13:30:53Z | |
dc.date.available | 2006-04-19T13:30:53Z | |
dc.date.issued | 2002-08-15 | en_US |
dc.identifier.citation | McGinn, Cornelius J.; Lawrence, Theodore S.; Zalupski, Mark M. (2002)."On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer." Cancer 95(S4): 933-940. <http://hdl.handle.net/2027.42/34363> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34363 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12209674&dopt=citation | en_US |
dc.description.abstract | The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group trials that have included 5-fluorouracil. Unfortunately, the majority of patients continue to succumb to the disease process. Recently, there has been a resurgence in clinical trials utilizing gemcitabine as a single agent, in combination chemotherapy regimens, and with concurrent radiation therapy. Use with concurrent radiation therapy is based in part on laboratory studies investigating mechanisms of radiosensitization and strategies that might increase the therapeutic index. In the current review, the authors summarize the preclinical data that support the use of gemcitabine as a radiosensitizing agent and the clinical trials that have been conducted to date. Issues regarding the use of gemcitabine in concurrent radiotherapy regimens need to be viewed in the context of both local and distant disease control, given the radiosensitizing and systemic activity of this agent. Cancer 2002;95:933–40. © 2002 American Cancer Society. DOI 10.1002/cncr.10754 | en_US |
dc.format.extent | 110839 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan Health Systems, Ann Arbor, Michigan ; Fax: (734) 763-7370 ; Department of Radiation Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0010 | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 12209674 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34363/1/10754_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.10754 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.